Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.1% - Here's What Happened

Key Points

• Structure Therapeutics shares fell 6.1% to about $32.93, with trading volume roughly 46% below the average session volume.
• Despite the decline, analysts maintain a consensus “Moderate Buy” rating with an average price target of $110.91, although ratings range from Strong Buy to Sell.
• The company reported a quarterly EPS loss of $0.49, missing expectations by $0.10. Institutional investors own 91.78% of the stock, while the company continues developing its oral GLP-1 drug GSBR-1290 for obesity and type 2 diabetes.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report)'s share price dropped 6.1% on Tuesday. The company traded as low as $33.04 and last traded at $32.9330. Approximately 497,334 shares were traded during trading, a decline of 46% from the average session volume of 920,710 shares. The stock had previously closed at $35.06.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Canaccord Genuity Group set a $111.00 price objective on shares of Structure Therapeutics in a report on Friday, August 7th. Wall Street Zen upgraded Structure Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Monday, August 17th. Citizens Jmp reissued a "market outperform" rating and set a $110.00 price objective on shares of Structure Therapeutics in a report on Wednesday, September 9th. Weiss Ratings downgraded Structure Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, September 18th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Structure Therapeutics in a report on Wednesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $110.91.

Structure Therapeutics Trading Down 6.4%

The company has a 50 day moving average of $46.25 and a 200 day moving average of $46.43. The firm has a market cap of $2.29 billion, a price-to-earnings ratio of -32.83 and a beta of -1.45.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. IFP Advisors Inc acquired a new position in shares of Structure Therapeutics during the second quarter worth $46,000. Squarepoint Ops LLC raised its stake in shares of Structure Therapeutics by 454.5% during the 2nd quarter. Squarepoint Ops LLC now owns 125,575 shares of the company's stock worth $6,740,000 after purchasing an additional 102,929 shares during the period. Seven Fleet Capital Management LP raised its stake in shares of Structure Therapeutics by 197.8% in the second quarter. Seven Fleet Capital Management LP now owns 26,800 shares of the company's stock valued at $1,442,000 after buying an additional 17,800 shares during the period. Wellington Management Group LLP raised its position in shares of Structure Therapeutics by 1.6% in the second quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company's stock valued at $396,054,000 after purchasing an additional 119,146 shares during the period. Finally, Handelsbanken Fonder AB bought a new position in shares of Structure Therapeutics in the second quarter valued at approximately $1,041,000. Institutional investors and hedge funds own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing oral medicines for chronic diseases. The company uses its structure-based drug discovery platform to target G protein-coupled receptors (GPCRs), a large class of proteins involved in metabolic, cardiovascular and pulmonary functions.

Its lead program is GSBR-1290, also known as aleniglipron, an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist being developed for conditions including obesity and type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.